R&D manufacturing site visit for investors and analysts
13 June 2017 - 9:42PM
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international
specialty pharmaceutical company focused on commercialising and
developing products in oncology, is hosting a site visit today at
its state-of-the-art manufacturing site in Bilbao, Spain for
institutional investors and sell-side analysts.
The site visit will be hosted by Jim Phillips, CEO and will
include presentations from Craig Cook, CMO, as well as a talk from
the perspective of a patient diagnosed with DIPG (diffuse intrinsic
pontine glioma) and treated with Midatech's lead R&D programme,
MTX110.
Programme updates will include:
- Q-Octreotide (MTD201) for carcinoid syndrome and acromegaly,
which is on track to start its first in human equivalence study
later this year versus Novartis' market leading Sandostatin LAR
product
- Childhood brain cancer program (MTX110), which is now rapidly
moving towards a Phase I/II study in the US and/or EU/UK, and
following the license deal with Novartis, announced last week
- Liver cancer programme (MTD119), which continues to show
encouraging efficacy results in pre-clinical models. The
latest orthotopic liver cancer study is underway and is already
showing higher anti-tumour effects compared to the current standard
of care, sorafenib
- Also included will be an update on the adult brain cancer
glioblastoma MTR103 program, as well as the Group's pioneering
research in cancer immuno-therapy and the developing supportive
scientific rationale for using the Group's gold nano-particle
technology for cancer immuno-therapy
Attendees will be given a tour of the GMP manufacturing
facilities: the first plant licensed in Europe for nanoparticle
manufacture, which was recently upgraded to enable the manufacture
of sustained release products under clean conditions.
No new price sensitive information will be disclosed at the
event and presentations will be available on Midatech's website on
14th June 2017.
For more information, please contact:
Midatech Pharma PLC Jim Phillips, CEO Tel: +44 (0)1235 841575
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Corporate Finance Freddy Crossley / Duncan Monteith Broking Tom
Salvesen Tel: +44 (0)20 7886 2500
Consilium Strategic Communications (Financial PR) Mary Jane
Elliott / Ivar Milligan / Cameron Standage Tel: +44 (0)20 3709 5700
Email: midatech@consilium-comms.com
Westwicke Partners (US Investor Relations) Chris Brinzey Tel: +1
339 970 2843 Email: chris.brinzey@westwicke.com
Notes for Editors
About Sabine Mueller, MD, PhD
Dr Sabine Mueller is a paediatric neuro-oncologist who
specialises in caring for children with brain tumours and related
genetic syndromes. Before completing medical school, she worked as
a scientist, director of genomics and a project leader for a brain
tumour program at AGY, a biotechnology company in South San
Francisco.
In her research, she studies treatments for children with brain
tumours and improving the long-term cognitive outcome. Mueller
earned a medical degree at the Universitat Hamburg School of
Medicine and earned a PhD in biochemistry and molecular biology.
After a paediatric residency at Massachusetts General Hospital in
Boston, Mueller completed a fellowship in paediatric oncology at
UCSF. She is an assistant clinical professor of neurology,
neurological surgery and paediatrics.
About Midatech Pharma PLC
Midatech is an international specialty pharmaceutical company
focused on oncology and other therapeutic areas with a US
commercial operation marketing four cancer care supportive
products, and co-promoting two others. Midatech's strategy is to
internally develop oncology products and collaborate with partners
in other therapy areas, and to drive growth both organically and
through strategic acquisitions. The Company's R&D activities
are supported by two breakthrough drug delivery technologies:
Q-Sphera for sustained release and our proprietary gold
nanoparticles. The Group, listed on AIM: MTPH and Nasdaq: MTP,
employs c.110 staff in four countries. For further company
information see: www.midatechpharma.com
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From Apr 2024 to May 2024
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From May 2023 to May 2024